ArticleOncogene2017
Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07035249 (A Prospective, Single-Arm Clinical Trial Evaluating DCSZ11 Combined With Standard-of-Care Therapy in Patients With Advanced or Metastatic Solid Tumors), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Single-Arm Clinical Trial Evaluating DCSZ11 Combined With Standard-of-Care Therapy in Patients With Advanced or Metastatic Solid Tumors
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Oncologic feasibility for negative pressure wound therapy application in surgical wounds: A meta-analysis.International wound journal · 2022Pooled it
- Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape.The FEBS journal · 2026Review
- Rational design of hammerhead ribozymes as CD93 silencing tools for vascular diseases.Molecular therapy. Nucleic acids · 2026Article
- Unveiling prognostic genes and regulatory mechanisms of stress granules in gastric cancers: an integrated analysis of bulk transcriptomics and single-cell RNA sequencing.Frontiers in oncology · 2026Article
- CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Pericyte Expression of VEGF-A Minimally Impacts Ocular Vascular Development and Neovascularization.Cells · 2025Article
- CD93 in Health and Disease: Bridging Physiological Functions and Clinical Applications.International journal of molecular sciences · 2025Review
- [Overexpression of multimerin-2 promotes cutaneous melanoma cell invasion and migration and is associated with poor prognosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Ligand-Receptor Analysis of Brain Cell Type Marker Data Reveals Intricate Endothelial Interaction.Annals of neurosciences · 2025Article
- Pan-cancer analysis identified CD248 as a potential target for multiple tumor types.Frontiers in pharmacology · 2025Article
- Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning.Communications biology · 2024Article
- Group XIV C-type lectins: emerging targets in tumor angiogenesis.Angiogenesis · 2024Review
- Structural insight into CD93 recognition by IGFBP7.Structure (London, England : 1993) · 2024Article
- Article
- Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.Theranostics · 2024Review
- Regulation of matrix reloading by tumor endothelial marker 1 protects against abdominal aortic aneurysm.International journal of biological sciences · 2024Article
- [Expression of endosialin in human hypertrophic scars and its regulation on fibroblast phenotype].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2023Article
- Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization.Cancer cell international · 2023Review
- The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential.International journal of molecular sciences · 2023Review
- Role of CD93 in Health and Disease.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The C-type lectin domain containing group 14 family members CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family and is expressed by tumour-associated fibroblasts and pericytes. Multimerin-2 (MMRN2) is a unique endothelial specific extracellular matrix protein that has been implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent on a predicted long-loop region in the C-type lectin domain and is abrogated by mutation within the domain. CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2 spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial cell surface as well as increasing adherence of human umbilical vein endothelial cells to the active peptide. This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These findings identify novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.